Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential cation channel subfamily C member 4 associated protein (TRPC4AP) is a human protein encoded by the *TRPC4AP* gene. It functions primarily as a substrate-specific adaptor in the DDB1-CUL4-X-box (DCX) E3 ubiquitin ligase complex, where it mediates the polyubiquitination and subsequent degradation of proteins such as MYC by recognizing C-terminal degron motifs. TRPC4AP is also involved in the ubiquitin-dependent protein catabolic process, cell cycle regulation, and may contribute to the activation of signaling pathways downstream of the tumor necrosis factor receptor (TNFRSF1A), including NF-κB and c-Jun N-terminal kinase via its interaction with TRAF2. It is expressed ubiquitously in human tissues and shows altered expression in certain disease states, such as Alzheimer’s disease and cancer. There are currently no approved drugs targeting TRPC4AP, nor is it considered a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential cation channel subfamily C member 4 associated protein (TRPC4AP).